RGNX
Regenxbio Inc
Halal Rating :
Last Price
$7.37
Last updated:
Market Cap
-
7D Change
5.97%
1 Year Change
-48.13%
Company Overview
Industries
Exchange
Next Earnings Date
REGENXBIO Inc. is a clinical-stage biotechnology company focused on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company develops treatments for various diseases including wet age-related macular degeneration, diabetic retinopathy, and other rare genetic conditions. Their proprietary NAV Technology Platform allows for the development of gene therapies that can potentially treat both rare and large-market diseases.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $24.2m | $87.09m | - | $820000.0 | 0.00% | 0.94% |
| June 30, 2024 | $22.3m | $78.78m | - | $449000.0 | 0.00% | 0.57% |
| March 31, 2024 | $15.62m | $81.46m | - | $1.97m | 0.00% | 2.42% |
Company Impact
Help us evaluate Regenxbio Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.